Clinical Trial Update: Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This document reports a Phase 1/2 trial of grapiprant plus eribulin for metastatic inflammatory breast cancer, which was terminated and whose results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Inflammatory Breast Cancer

Drugs mentioned

• Grapiprant (grapiprant)
• Halaven (eribulin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-06-13